Loading…
Lobbying Income
$6.8M
Filings
190
Unique Clients
25
Active Period
2024–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mikaela Naylon Give Kids a Chance Act
2026 · third_quarter · Client: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1262
Give Kids a Chance Act of 2025
2026 · third_quarter · Client: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: S.932
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1492
Medical Supply Chain Resiliency Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2213
EPIC Act of 2025
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: S.832
Health issues. Medicare/Medicaid issues. H.R.5269: RESULTS Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5269
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2026 · third_quarter · Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION
Health programs impacting MDMA. Issues related to medical devices. Issues related to FDA approval of medical devices. Issues related to sterilization of medical devices. Barriers to market access for medical device companies. Issues related to the coverage for FDA Breakthrough products and the H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medical Device User Fee Amendments (MDUFA) implementation. Issues related to physician fee schedule. Issues related to coverage of telehealth services. Issues related to regulation and reimbursement of artificial intelligence in healthcare. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Supply chain issues. Cyber security issues related to consumer and health data privacy. TCET Issues related to the New Technology Add on Payment (NTAP).
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1691
Mikaela Naylon Give Kids a Chance Act
2026 · third_quarter · Client: IONIS PHARMACEUTICALS, INC.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1262
Maintaining Investments in New Innovation Act
2026 · third_quarter · Client: IONIS PHARMACEUTICALS, INC.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1672
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.946
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: S.1862
Give Kids a Chance Act of 2025
2026 · third_quarter · Client: IONIS PHARMACEUTICALS, INC.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: S.932
Patients Deserve Price Tags Act
2026 · third_quarter · Client: ERISA INDUSTRY COMMITTEE (ERIC)
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.
Client expense: — · Firm income: $30,000
Matched citations: S.2355
Increasing Prescription Drug Competition Act
2026 · second_quarter · Client: AVADEL PHARMACEUTICALS PLC
Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. VA Appropriations Request.
Client expense: — · Firm income: $60,000
Matched citations: H.R.4692
Increasing Prescription Drug Competition Act
2026 · second_quarter · Client: AVADEL PHARMACEUTICALS PLC
Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. VA Appropriations Request.
Client expense: — · Firm income: $60,000
Matched citations: S.574
Maintaining Investments in New Innovation Act
2026 · third_quarter · Client: Alnylam Pharmaceuticals, Inc.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1672
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: H.R.946
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Client expense: — · Firm income: $50,000
Matched citations: S.1862
Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R.946
Mikaela Naylon Give Kids a Chance Act
2026 · second_quarter · Client: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1262
Give Kids a Chance Act of 2025
2026 · second_quarter · Client: PTC THERAPEUTICS, INC.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: S.932
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1492
Medical Supply Chain Resiliency Act
2026 · second_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2213
EPIC Act of 2025
2026 · second_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Client expense: — · Firm income: $30,000
Matched citations: S.832
Coverage and reimbursement for innovative lab-developed tests. H.R.5269: RESULTS Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.5269
Source: Senate LDA